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ABSTRACT 
 
We examined whether zoledronic acid (ZOL), the third generation of bisphosphonates, 
produced cytotoxic effects on human mesothelioma cells, most of which possessed the 
wild-type p53 gene. ZOL treatments increased sub-G1 phase fractions with activation of 
caspases and with attenuated mitochondrial membrane potential, or augmented S phase 
populations with down-regulated p21. Inhibition of extracellular signal regulated kinase1/2 
pathways suppressed ZOL-induced apoptosis but not S phase arrest. We also observed that 
ZOL induced p53 phosphorylation at Ser 15, a marker of p53 activation, and induced 
subsequent activation of p53 downstream pathways. Down-regulated p53 expression with the 
siRNA however demonstrated that both apoptosis and S phase arrest were irrelevant to the 
p53 activation. ZOL influenced prenylation and localization of small G proteins, and 
supplementary geranylgeranyl and farnesyl pyrophosphate decreased the ZOL-mediated 
small G proteins ungeranygeranylation and unfarnesylation, respectively. The geranylgeranyl 
pyrophosphate supplement inhibited ZOL-induced apoptosis and S phase arrest but not 
farnesyl pyrophosphate supplement. A combinatory use of ZOL and cisplain (CDDP), one of 
the first-line anti-cancer agents for mesothelioma, synergistically or additively enhanced the 
cytotoxicity to mesothelioma cells. The synergism disappeared in p53 down-regulated 
mesothelioma cells with the siRNA. In addition, ZOL treatments augmented cytotoxicity of 
adenoviruses expressing the p53 gene to mesothelioma. We also demonstrated the anti-tumor 
effects of intrapleurally administrated ZOL in an orthotopic animal model. The combinatory 
treatment of ZOL and CDDP produced greater anti-tumor effects on mesothelioma developed 
in the pleural cavity than administration of either ZOL or CDDP alone. These data indicate 
that ZOL induces apoptosis or S phase arrest, both of which are caused by 
ungeranylgeranylation of small G proteins, and suggest that ZOL-mediated up-regulation of 
p53 pathways, although not linked with ZOL-induced cytotoxicity, played a crucial role in 
the combinatory effects with CDDP. ZOL alone or together with CDDP is possible novel 
therapeutics to mesothelioma patients. 
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INTRODUCTION 
 
The majority of mesothelioma is associated with asbestos exposure and asbestos 
consumption data predict increased incidences in industrial countries [1, 2]. Approximately 
80% of mesothelioma cells have the wild-type (WT) p53 gene, while the INK4A/ARF locus 
encoding the p14ARF and the p16INK4A genes are commonly deleted [3, 4]. Prognosis of 
mesothelioma is enormously poor, with 6 to 12 months of median survival time after the 
diagnosis [1, 5]. Surgical extrapleural pneumonectomy can be applicable only for the patients 
in an early clinical phase and mesothelioma cells are in general resistant to radiation and 
chemotherapeutic agents despite multiple treatment modalities [1, 2, 5]. A combination of 
cisplatin (CDDP) and pemetrexed is currently the first-line agents but an average survival 
period with the agents is about 12 months [6]. The clinical outcome even with the updated 
combinatory chemotherapy is thus unsatisfactory. 
Bisphosphonates (BPs) are synthetic analogues of pyrophosphate and have a strong affinity 
for mineralized bone matrix [7]. BPs can inhibit bone absorption by acting on osteoclasts, and 
are currently used for bone lesions such as osteoporosis and hypercalcemia. Recent reports 
demonstrated that BPs also achieved cytotoxicity on tumor cells with multiple mechanisms 
including apoptosis induction and produced anti-tumor effects in vivo [8]. The BPs-induced 
benefits in vivo were evidenced with osseous tumors or with bone metastasis of non-osseous 
tumors [9]. Only a few previous studies demonstrated the anti-tumor effects in vivo with 
non-osseous tumors because BPs accumulated in bone tissues but readily excreted from body 
[10]. The mechanism of BPs-mediated cytotoxicity is dependent on BPs structures [7, 8]. The 
first generation of BPs stimulates production of non-hydrolyzable cytotoxic ATP analogues 
and decreases mitochondrial membrane potential (ΔΨm). The second and third generations 
instead inhibit farnesyl pyrophosphate (FPP) synthetase, a key enzyme in the mevalonate 
pathways, and deplete isoprenoid pools, which subsequently result in decreased prenylation 
of small guanine-nucleotide-binding regulatory proteins (small G proteins) (Figure 1). The 
unprenylation influences activities of the small G proteins, which plays a crucial role in a 
variety of biological functions including cell survival [11, 12]. It remains uncharacterized as 
to the precise mechanisms of cytotoxicity induced by down-regulated functions of small G 
proteins although several lines of experiments showed that BPs inhibited prenylation of Ras, 
Rho and Rab family proteins [13-15]. A possible p53 involvement in ZOL-induced 
cytotoxicity also was not well investigated. 
In the present study, we examined cytotoxic effects of zoledronic acid (ZOL), one of the 
third generation of BPs, on human mesothelioma cells and investigated the possible 
anti-tumor activities in the context of p53 and involvements of small G proteins. We 
demonstrated that mesothelioma cells were susceptible to ZOL by inducing p53-independent 
apoptosis or S phase arrest and that inhibited granylgeranylation of small G proteins 
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contributed to the cytotoxic and cytostatic activities. We also investigated a possible 
combinatory use of CDDP with ZOL on mesothelioma cells and the combination produced 
synergistic effects via p53-mediated pathways. Furthermore, treatments of ZOL alone and 
together with CDDP produced anti-tumor effects on mesothelioma developed in the pleural 
cavity. 
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Figure 1. An outline of ZOL- and the related molecules-mediated actions 
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MATERIALS AND METHODS 
 
Cells and mice 
Human mesothelioma cells, MSTO-211H, NCI-H28, NCI-H226, NCI-H2052 and 
NCI-H2452, and immortalized mesothelial cells, Met-5A, were purchased from American 
Type Culture Collection (Manassas, VA, USA). Other human mesothelioma cells, JMN-1B, 
EHMES-1 and EHMES-10 cells were kindly provided by Dr Hamada (Ehime Univ., Ehime, 
Japan) [16]. Normal human fibroblasts, OUMS-24, obtained from foreskin were kindly 
provided by Dr Namba (Niimu College, Okayama, Japan) [17]. The p53 status of JMN-1B 
and EHMES-1 cells are mutated and that of the others are WT, whereas the all mesothelioma 
cells have deficient expressions of p14ARF and p16INK4A due to either loss of the transcription 
or deletion of the genomic DNA (Figure 2). In contrast, Met-5A and OUMS-24 cells have the 
WT p14ARF and p16INKA genes. BALB/c nu/nu and C57BL/6 mice (6-week-old females) were 
purchased from Japan SLC (Hamamatsu, Japan). 
 
Adenoviruses (Ad) preparation 
Replication-incompetent type 5 Ad expressing the WT p53 gene (Ad-p53) or the 
β-galactosidase gene (Ad-LacZ), in which the cytomegalovirus promoter activated 
transcription of the transgene, were prepared with an Adeno-X expression vector system 
(Takara, Shiga, Japan). The amount of Ad-p53 was expressed as viral particles (vp). 
 
Agents 
ZOL was purchased from Novartis Pharmaceuticals (Tokyo, Japan). CDDP was purchased 
from Bristol-Myers Squibb (New York, USA). Farnesol (FOH), geranylgeraniol (GGOH) and 
GGTI-298 were purchased from Sigma-Aldrich (St. Louis, MO, USA). Epidermal growth 
factor (EGF) was purchased from Wako (Osaka, Japan). PD98059 and NSC23766 were 
purchased from Calbiochem-Merck (Darmstadt, Germany). C3 transferase was purchased 
from Cytoskeleton (Denver, CO, USA). NE10790 was kindly provided by Dr Ebetino FH 
(Warner Chilcott, Dundalk, Ireland) [18].  
 
RNA interference 
Cells were transfected with small interfering RNA (siRNA) duplex targeting p53 or Cdc42, 
or non-specific siRNA control (Invitrogen, Carlsbad, CA, USA) for 24 h using Lipofectamine 
RNAiMAX according to the manufacturer’s protocol (Invitrogen). 
 
Polymerase chain reaction (PCR) and reverse transcription-PCR (RT-PCR) analyses 
DNA and RNA were isolated from cultured cells. The total RNA was used to synthesize 
first-strand cDNA with Superscript III reverse transcriptase (Invitrogen), and amplification of 
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equal amounts of the cDNA was performed the following primers and conditions: for the 
p14ARF gene, 5′-TTCTTGGTGACCCTCCGGATT-3′ (sense), 
5′-TGCCCATCATCATGACCTGG-3′ (anti-sense) and 30 s at 94 °C/30 s at 56 °C/30 s at 
72 °C/32 cycles; for the p16INK4A gene, 5′-GGAGCAGCATGGAGCCTT-3′ (sense), 
5′-TGCCCATCATCATGACCTGG-3′ (anti-sense) and 30 s at 94 °C/30 s at 56 °C/30 s at 
72 °C/32 cycles; for the GAPDH gene, 5′-GGAGCAGCATGGAGCCTT-3′ (sense), 
5′-TGCCCATCATCATGACCTGG-3′ (anti-sense) and 15 s at 94 °C/15 s at 60 °C/40 s at 
72 °C/25 cycles. RCR of the genomic DNA was performed as follows: for exon 1β of the 
p14ARF gene, 5′-TGCGTGGGTCCCAGTCTGCA-3′ (sense), 
5′-GGCGGTTATCTCCTCCTCCTCC-3′ (anti-sense) and 60 s at 94 °C/60 s at 61 °C/60 s at 
72 °C/30 cycles; for exon 2 of the p14ARF and p16INK4A genes, 
5′-TCTGACCATTCTGTTCTCTC-3′ (sense), 5′-CTGAGCTTTGGAAGCTCTCA-3′ 
(anti-sense) and 60 s at 94 °C/60 s at 52 °C/60 s at 72 °C/38 cycles; for exon 3 of the p14ARF 
and the p16INK4A genes, 5′-GGATGTGCCACACATCTTTG-3′ (sense), 
5′-ATGAAAACTACGAAAGCGGG-3′ (anti-sense) and 60 s at 94 °C/60 s at 52 °C/60 s at 
72 °C/35 cycles. 
 
Cell proliferation and viability test 
Cell viabilities were assessed with a WST-8 reagent (Dojindo, Kumamoto, Japan) and the 
amounts of formazan produced were determined with the absorbance at 450 nm (WST assay). 
The relative viabilities were calculated based on the absorbance without any treatments. Half 
maximal inhibitory concentration (IC50) and combination index (CI) values at the fraction 
affected (Fa), which showed relative suppression levels of cell viability, were calculated with 
CalcuSyn software (Biosoft, Cambridge, UK). Fa=1 and Fa=0 indicate 0% and 100% 
viability tested with the WST assay, respectively, and CI<1, CI=1 and CI>1 indicate 
synergistic, additive and antagonistic actions, respectively. Viable cell numbers after ZOL 
treatments were counted on the basis of the trypan blue dye exclusion test. 
 
Flow cytometry 
For cell cycle analysis, cells were fixed with 100% ethanol, treated with 50 μg/ml of 
RNaseA for 15 min, and stained with 50 μg/ml of propidium iodide. For detecting ΔΨm, cells 
treated with several agents were stained with a JC-1 reagent according to the manufacturer’s 
instruction (ImmunoChemistry Technologies, Bloomington, MN, USA) and the fluorescence 
intensity was analyzed with FACSCalibur and CellQuest software (BD, San Jose, CA, USA). 
 
Western blot analysis 
Cell lysates were subjected to SDS-PAGE and the proteins were transferred to a 
nitrocellulose membrane, which was further reacted with, anti-phospho-p53 at Ser15, 
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anti-caspase-3, anti-cleaved caspase-3, anti-caspase-8, anti-cleaved caspase-8, anti-caspase-9, 
anti-cleaved caspase-9, anti-Bax, anti-phospho-extracellular signal regulated kinase1/2 
(ERK1/2) at Thr202/Tyr204, anti-Bcl-2, anti-PARP, anti-Rb, anti-phospho-Rb at Ser795 (Cell 
Signaling, Beverly, MA, USA), anti-Mdm2, anti-p21, anti-cyclin A, anti-cyclin B1, 
anti-unprenylated Rap1A, anti-Rap1, anti-Mcl-1, anti-Rab6 (Santa Cruz Biotechnology, Santa 
Cruz, CA, USA), anti-Ras, anti-p27, anti-ERK1/2 (BD), anti-p53 (Thermo Fisher Scientific, 
Fremont, CA, USA), anti-RhoA, anti-Rac1, anti-Cdc42 (Cytoskeleton) or anti-actin antibody 
(Sigma-Aldrich) as a control followed by an appropriate second antibody. The membranes 
were developed with the ECL system (GE Healthcare, Buckinghamshire, UK). Membrane 
and cytoplasm fractions were separated with a native membrane protein extraction kit 
according to the manufacturer’s protocol (Calbiochem-Merck) and intensity of the respective 
bands was determined using the public domain Image J program (available at 
http://rsbweb.nih.gov/ij). 
 
Caspase activities 
Cells treated with ZOL were tested for the activity of caspase-3/7, -8 or -9 with respective 
Caspase-Glo kits according to the manufacturer’s protocol (Promega, Madison, WI, USA). 
The relative activity level was calculated based on luminescence intensity of cells without 
any treatments. 
 
Apoptotic DNA ladder formation 
Genomic DNA was isolated from MSTO-211H cells, untreated or treated with ZOL or 
CDDP, using an apoptotic DNA ladder kit (Roche Diagnostics, Indianapolis, USA). 
 
Animal experiments 
MSTO-211H cells or EHMES-10 cell were injected into the pleural cavity of BALB/c 
nu/nu mice and ZOL (15 or 40 μg) or the same amount of phosphate-buffered saline (PBS) as 
a control was administrated intrapleurally on day 3 or 10. The mice were sacrificed on day 25 
(MSTO-211H cells) or 35 (EHMES-10 cells), and the tumor weights were measured. In 
combinatory treatments of ZOL and CDDP, MSTO-211H cells were injected into the pleural 
cavity of BALB/c nu/nu mice. ZOL (25 μg) or PBS was administrated intrapleurally on day 3 
and CDDP (100 μg) or PBS was injected into the peritoneal cavity on day 5. The mice were 
sacrificed on day 24 and the tumor weights were measured. The animal experiments were 
approved by the animal experiment and welfare committee at Chiba University, and were 
performed according to the guideline on animal experiments. 
 
Hematoxylin and eosin staining  
C57BL/6 mice were intrapleurally injected with ZOL (40 μg) or PBS and sacrificed on day 
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31. The parietal mesothelium samples were fixed with 10% formalin and stained with 
hematoxylin and eosin. 
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Figure 2. Deletion or loss of expressions in the p14ARF and the p16INK4A genes in 
mesothelioma. (a) PCR to detect the INK4A/ARF locus, which encodes the p14ARF gene 
consisting of the exon 1β, 2 and 3, and the p16INK4 gene consisting of the exon 1α, 2 and 3. 
The exons 2 and 3 are shared with the p14ARF and the p16INK4 genes. Met-5A and OUMS-24 
cells were used as controls. (b) RT-PCR to detect the p14ARF and the p16INK4A transcripts with 
primer sets spanning from the exon 1β to the exon 2 and from the exon 1α to the exon 2, 
respectively. 
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RESULTS 
 
Anti-tumor effects of ZOL in vitro and in vivo 
We examined cytotoxic activities of ZOL in 8 human mesothelioma cells with the WST 
assay (Figure 3). All of the cells were more sensitive to ZOL than pancreatic carcinoma 
PANC-1 cells which were demonstrated to be susceptible to ZOL [19]. The IC50 values of 
ZOL in all the human mesothelioma cells tested were less than 10 μM, while those in other 
human tumors were reported as 10-85 μM [7, 20].  
We investigated ZOL-induced anti-tumor effects in an orthotopic animal model with 2 
treatment schedules. Nude mice were injected with mesothelioma cells in the pleural cavity 
and received ZOL treatment intrapleurally. All the tumors were found in the pleural cavity 
without any detectable metastatic foci. Administration of 40 μg ZOL on day 3 inhibited the 
tumor growth in mice injected with MSTO-211H or EHMES-10 cells in comparison with the 
PBS-injected group and the inhibition was in a dose-dependent manner (Figure 4a and 4b). 
As the second model, we injected 40 μg ZOL into the mice on day 10. Some of the mice in 
the second model were sacrificed on day 10 after tumor inoculation and the tumor 
development (35 mg in average) was confirmed in all the mice examined. The delayed ZOL 
administration diminished the anti-tumor effects but the inhibitory effects of ZOL were also 
produced compared with PBS injection (Figure 4c). 
 
Differential effects on cell cycle 
We investigated ZOL effects on cell cycle progression with flow cytometry and found that 
ZOL treatments increased sub-G1 and S phase populations depending on the cells tested. 
Sequential examinations with different treated periods and concentrations revealed that ZOL 
treatments induced 2 characteristic cell cycle patters, increased sub-G1 populations without 
cell cycle arrest at S phase which was evidenced in MSTO-211H cells and augmented S 
phase fractions without sub-G1 phase increase in EHMES-10 cells (Figure 5a and Table 1). 
We also found that ZOL decreased numbers of MSTO-211H cells and suppressed 
proliferation rates of EHMES-10 cell with the cell count assay (Figure 5b). Other cells 
showed increase of S phase populations and then that of sub-G1 phase fractions with flow 
cytometry (for JMN-1B and EHMES-1 cells, see Figure 10a and Table 3). MSTO-211H and 
EHMES-10 cells were thus representatives that induced cell death and S phase arrest, 
respectively, and were used for further analyses.  
We examined expression levels of molecules that were associated with cell death and S 
phase arrest with Western blot analyses. Caspase-8 and caspase-9, which are linked with the 
extrinsic and the intrinsic apoptosis pathways, respectively, were cleaved in ZOL-treated 
MSTO-211H cells and the respective uncleaved caspase expressions accordingly decreased 
(Figure 6a). Caspase-3 and PARP were likewise cleaved with decreased the uncleaved 
 
 
- 11 - 
 
expression levels (Figure 6a and 6b). These caspase cleavages in MSTO-211H cells were 
observed after 48 h when sub-G1 phase populations increased. Test of the substrate-cleaving 
activities also showed caspases activation following ZOL treatments for 72 h. ZOL 
treatments at 1 μM did not induce activation of respective caspases but those at 10 μM did in 
MSTO-211H cells (Figure. 6c). In addition, we detected the apoptotic DNA ladders in 
MSTO-211H cells, indicating that ZOL-mediated cell death was apoptosis. (Figure 6d). ZOL 
treatments increased expression of Bax, a proapoptotic Bcl-2 family protein, and decreased 
that of Mcl-1, an anti-apoptotic Bcl-2 family protein, in MSTO-211H cells (Figure 6a). The 
modulated expression patterns of the Bcl-2 family proteins might be involved in ΔΨm. We 
thus examined a possible involvement of mitochondria-mediated apoptosis pathways in 
MSTO-211H cells with a JC-1 agent. ZOL treatments reduced the JC-1 fluorescence intensity 
in a dose-dependent manner (Figure 6e). These results demonstrated that ZOL-induced cell 
death was caspases-dependent apoptosis via mitochondria pathways. 
In contrast, ZOL scarcely or minimally changed the expression levels of Mcl-1, Bax, 
cleaved PARP and cleaved caspases in EHMES-10 cells (Figure 6a and 6b) but increased 
expression levels of cyclin A and B1 which were markers of S phase arrest (Figure 7a) [21]. 
MSTO-211H cells also showed transient increase of cyclin A and B1 expressions at 24 h and 
the decrease thereafter in accordance with no arrest at S phase. ZOL treatments increased 
phosphorylation of ERK, maintained Rb phosphorylation and decreased p21 expression in 
EHMES-10 cells but not in MSTO-211H cells (Figure 7a and 7b). The phospholyation of 
ERK and Rb promotes G1/S phase transition, and p21, a CDK inhibitor, represses the cell 
cycle progression [21], which suggests that ZOL-increased S phase populations are resulted 
from abnormal facilitation in G1/S phase transition.  
 
ERK1/2 pathways linked with apoptosis but not with S phase arrest 
ZOL treatments increased phosphorylation of ERK1/2 in EHMES-10 cells but decreased 
the phosphorylation in MSTO-211H (Figure 8b). We thus examined a possible involvement 
of ERK1/2 pathways in the ZOL-mediated S phase arrest. We firstly confirmed that EGF 
induced phosphorylation of ERK1/2 in both MSTO-211H and EHMES-10 cells [22], 
suggesting that the upstream pathways of ERK1/2 were maintained in both cells (Figure 8a). 
PD98059, an inhibitor of ERK kinase1/2 (MEK1/2) which was located in an upstream site of 
ERK1/2 [23], inhibited endogenous ERK1/2 phosphorylation in both cells. Treatments with 
PD98059 prior to ZOL further decreased the phosphorylation in MSTO-211H cells and 
inhibited the ZOL-induced augmented phosphorylation in EHMES-10 cells (Figure 8b). 
We examined whether ERK1/2 down-regulation influenced the ZOL-induced cell cycle 
progression (Figure 8c and Table 2). PD98059 alone did not markedly influence the cell cycle, 
whereas PD98059 treatments inhibited ZOL-mediated increase of sub-G1 phase populations 
in MSTO-211H cells. PD98059 however did not affect the ZOL-induced S phase arrest in 
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EHMES-10 cells. In accordance with the cell cycle, PD98059 suppressed caspase-9 and -3 
cleavages in MSTO-211H cells but did not influence cyclin A expression levels in 
EHMES-10 cells (Figure 8b). These data demonstrated that ERK1/2 pathways mediated the 
ZOL-induced apoptosis but were irrelevant to the S phase arrest although PD98059 inhibited 
the ERK1/2 phosphorylation in both cells. 
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Figure 3. Cytotoxic effects of ZOL. Cells were treated with ZOL for 5 days and the cell 
viabilities were measured with the WST assay. The relative viabilities were calculated based 
on the absorbance without any treatments. Means of triplicated samples and SE bars are 
shown.  
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Figure 4. ZOL-mediated anti-tumor effects in an orthotopic animal model. Cells (1X106) 
were inoculated into the pleural cavity in BALB/c nu/nu mice and then ZOL or PBS as a 
control was intrapleurally administrated on (a) day 3 or (c) 10. (a) Tumor weights were 
measured on day 25 (MSTO-211H cells) or 35 (EHMES-10 cells) (n=6 or 7). (b) 
Macroscopic findings of the pleural cavity of mice in (a). The arrows indicate the tumors 
developed in the pleural cavity. (c) Some of the mice intrapleurally injected with 
MSTO-211H cells (n=6) were confirmed to bear the tumor development on day 10. The rest 
of mice were treated with ZOL (n=8) or PBS (n=7) on day 10 and were examined for the 
tumor weight on day 25. SE bars are also shown. * P < 0.05, ** P < 0.01. 
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Figure 5. ZOL-induced apoptosis or S phase arrest. (a) Flow cytometrical analyses of cell 
cycles of mesothelioma cells treated with ZOL for 48 h. (b) Cells (3×104) were cultured with 
or without ZOL and viable cells were counted with a trypan blue dye exclusion test. Means of 
triplicated samples and SE bars are shown. 
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Table 1  Cell cycle distribution after ZOL treatment  
Cell line  Cell cycle distribution (%) ± SE 
 Treatment Time Sub-G1 G0/G1 S G2/M 
MSTO-211H      
 (-) 24 h 1.00 ± 0.08 54.83 ± 0.46 19.34 ± 0.17 25.18 ± 0.37 
  48 h 2.66 ± 0.10a 78.68 ± 0.27 7.68 ± 0.27 10.82 ± 0.12 
  72 h 6.83 ± 0.15 82.23 ± 0.29 2.87 ± 0.16 8.68 ± 0.07 
 ZOL (10 μM) 24 h 2.12 ± 0.10 56.88 ± 0.33 18.19 ± 0.28 23.90 ± 0.24 
  48 h 4.75 ± 0.13a, b 80.28 ± 0.13 6.13 ± 0.19 9.38 ± 0.14 
  72 h 18.84 ± 0.12a, b 71.53 ± 0.21 3.09 ± 0.03 6.58 ± 0.14 
 ZOL (50 μM) 24 h 2.01 ± 0.16 64.58 ± 0.11 13.97 ± 0.18 19.78 ± 0.11 
  48 h 26.98 ± 0.76a, b 59.05 ± 0.53 4.37 ± 0.21 9.70 ± 0.07 
  72 h 79.14 ± 0.32a, b 15.65 ± 0.13 4.73 ± 0.06 1.22 ± 0.11 
EHMES-10      
 (-) 24 h 0.55 ± 0.07 69.86 ± 0.47 12.67 ± 0.38c 16.70 ± 0.21 
  48 h 0.79 ± 0.10 74.92 ± 0.46 11.61 ± 0.08c 13.28 ± 0.38 
  72 h 1.09 ± 0.05 78.40 ± 0.30 7.15 ± 0.16c 13.32 ± 0.30 
 ZOL (10 μM) 24 h 0.59 ± 0.04 68.48 ± 0.20 21.85 ± 0.15c 9.86 ± 0.08 
  48 h 0.58 ± 0.05 51.66 ± 0.54 39.31 ± 0.37c 9.54 ± 0.44 
  72 h 1.07 ± 0.02 39.08 ± 0.42 47.59 ± 0.41c 13.52 ± 0.44 
 ZOL (50 μM) 24 h 0.73 ± 0.03 66.22 ± 0.22 26.61 ± 0.28c 6.60 ± 0.21 
  48 h 0.94 ± 0.06 58.48 ± 0.49 34.83 ± 0.30c 6.78 ± 0.24 
  72 h 1.82 ± 0.06 55.92 ± 0.43 34.87 ± 0.28c 7.56 ± 0.16 
Cells were treated with or without ZOL. 
a P < 0.01, not treated vs 10 or 50 μM ZOL treated at respective times in sub-G1 phase. 
b P < 0.01, 10 vs 50 μM ZOL treated at respective times in sub-G1 phase. 
c P < 0.01, not treated vs 10 or 50 μM ZOL treated at respective times in S phase. 
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Figure 6. ZOL-caused apoptotic signals. (a, b) Western blot analyses to detect 
apoptosis-related molecules in ZOL-treated cells. Cleaved caspases were undetectable in 
EHMES-10 cells. (c) Caspase activations in MSTO-211H cells that were treated with ZOL 
for 3 days were assayed with respective luminescence-based kits. The activities of untreated 
cells were expressed as 100%. Means of triplicated samples and the SE bars are shown. * 
P<0.01. (d) Electrophoresis of genomic DNA from MSTO-211H cells treated with ZOL (50 
μM) or CDDP (20 μM). A positive control was DNA of apoptotic U937 cells provided by the 
manufacturer. (e) Flow cytometrical analyses for ΔΨm. Cells firstly were treated with GGOH 
(10 μM) for 3 h and then with ZOL for further 48 h. Cells were also treated with 0.1% 
dimethyl sulfoxide as a solvent control or with 50 μM carbonyl cyanide m-chlorophenyl 
hydrazone (CCCP) for 1 h as a control for mitochondrial depolarization. Means of triplicated 
samples with SE bars are shown. * P < 0.01. 
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Figure 7. ZOL-promoted G1/S phase progression. (a, b) Cells were treated with ZOL and 
subjected to Western blot analyses to detect phosphorylation and expressions of S 
phase-related molecules. 
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Figure 8. Involvement with ERK1/2 pathways in ZOL-induced apoptosis and S phase arrest 
cells. (a) Cells were treated with recombinant EGF (10 ng/ml). (b, c) Cells were treated with 
PD98059 (20 μM) for 2 h and then further treated with ZOL (50 μM) for 48 or 72 h. They 
were subjected to (a, b) Western blot analyses or (c) cell cycle analyses (data at 48 h are 
shown). 
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Table 2  Influence of PD98059 on ZOL-induced cell cycle distribution  
Cell line  Cell cycle distribution (%) ± SE 
 Treatment Time Sub-G1 G0/G1 S G2/M 
MSTO-211H      
 (-) 48 h 3.63 ± 0.09a 80.73 ± 0.07 5.10 ± 0.20 10.67 ± 0.16 
  72 h 3.46 ± 0.04a 89.93 ± 0.27 2.19 ± 0.14 4.46 ± 0.13 
 PD98059 48 h 2.33 ± 0.06b 80.97 ± 0.34 5.86 ± 0.25 11.02 ± 0.16 
  72 h 1.84 ± 0.05b 92.00 ± 0.19 2.17 ± 0.04 4.03 ± 0.14 
 ZOL 48 h 34.13 ± 0.90a, c 55.47 ± 0.55 3.19 ± 0.23 7.41 ± 0.21 
  72 h 78.55 ± 0.43a, c 17.23 ± 0.37 3.54 ± 0.07 1.01 ± 0.02 
 PD98059 + ZOL 48 h 12.28 ± 0.21b, c 75.01 ± 0.20 5.23 ± 0.07 7.65 ± 0.25 
  72 h 68.50 ± 0.24b, c 27.26 ± 0.36 3.01 ± 0.15 1.51 ± 0.01 
EHMES-10      
 (-) 48 h 1.00 ± 0.06 74.68 ± 0.30 11.15 ± 0.47d 13.38 ± 0.62 
  72 h 0.76 ± 0.04 85.80 ± 0.31 5.59 ± 0.06d 7.94 ± 0.19 
 PD98059 48 h 1.43 ± 0.10 80.09 ± 0.38 9.38 ± 0.02e 9.33 ± 0.35 
  72 h 1.48 ± 0.16 85.45 ± 0.14 5.81 ± 0.24e 7.46 ± 0.20 
 ZOL 48 h 2.57 ± 0.13 56.04 ± 0.56 36.39 ± 0.51d 5.74 ± 0.17 
  72 h 5.45 ± 0.16 56.91 ± 0.10 33.61 ± 0.20d, f 4.81 ± 0.08 
 PD98059 +ZOL 48 h 2.71 ± 0.08 52.58 ± 0.11 42.78 ± 0.26e 3.02 ± 0.18 
  72 h 5.33 ± 0.23 29.56 ± 0.79 58.88 ± 1.07e, f 7.16 ± 0.20 
Cells were treated with 50 μM ZOL, 20 μM PD98059 or both. 
a P < 0.01, not treated vs ZOL treated at respective times in sub-G1 phase. 
b P < 0.01, PD98059 vs PD98059 and ZOL treated at respective times in sub-G1 phase. 
c P < 0.01, ZOL vs PD98059 and ZOL treated at respective times in sub-G1 phase. 
d P < 0.01, not treated vs ZOL treated at respective times in S phase. 
e P < 0.01, PD98059 vs PD98059 and ZOL treated at respective times in S phase. 
f P < 0.01, ZOL vs PD98059 and ZOL treated at respective times in S phase. 
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ZOL-activated p53 pathways 
We examined a possible activation of p53 pathways in MSTO-211H and EHMES-10 cells. 
We firstly demonstrated that CDDP treatments up-regulated p53 protein levels and caused 
p53 phosphorylation at Ser15 residue, a marker of p53 activation, and caspase-3 cleavage in 
both cells, demonstrating that the p53 pathways were functional (Figure 9a) [24]. These cells 
were then subjected to apoptotic cell death (data not shown). ZOL treatments also induced 
phosphorylated p53 at Ser15 in both cells although up-regulation of p53 expression levels 
was observed only in EHMES-10 cells (Figure 9b). Further examinations showed elevated 
expression levels of p53 targets [25, 26], cleaved Mdm2 at 60 kDa, Bcl-2 and Bax (Figure 
6a). MSTO-211H cells also showed increased p27 expression but EHMES-10 cells did not. 
The treatment at 50 μM for 72 h induced cell death in MSTO-211H cells and subsequently 
expression levels of these p53-related proteins were down-regulated. In addition, reverse 
transcription-polymerase chain reaction assays showed that ZOL increased transcripts of 
p53-target genes, Puma and Noxa (data not shown) in both cells. These data suggested that 
ZOL treatments activated p53 and the downstream pathways although the activation was 
dependent on cells. 
 
Induction of apoptosis and S phase arrest in a p53-independent manner 
JMN-1B and EHMES-1 cells contain a mutation in the p53 gene at G245 and R273, 
respectively, which are mapped to a frequent mutation site within the DNA binding region 
[27]. The cell lines were as sensitive to ZOL as the other p53-WT mesothelioma cells (Figure 
3) and ZOL treatments induced S phase arrest and subsequent apoptotic cell death (Figure 
10a and Table 3), suggesting that p53 activation was not essential for the cytotoxic effects by 
ZOL. 
We further investigated p53 involvements in the apoptosis and the S phase arrest by 
silencing p53 with p53-specific siRNA. Transfection of p53-siRNA suppressed p53 
expression levels and inhibited the phosphorylation irrespective of ZOL treatments (Figure 
10b). ZOL-mediated cleavages of caspase-9 and -3 were not however influenced with the 
siRNA treatments in MSTO-211H cells. Introduction of the siRNA alone increased cyclin A 
expressions in MSTO-211H cells probably because inhibiting endogenous p53 resulted in cell 
cycle progression, and in fact temporally increased the S phase fraction (Figure 10c and Table 
4) and the cell proliferation (data not shown). Expressions of cleaved caspase-9 and -3, and 
cyclin A in ZOL-treated EHMES-10 cells were not affected by the siRNA treatments (Figure 
10b) Cell cycle analyses demonstrated that the siRNA transfection did not influence 
ZOL-mediated increase of sub-G1 populations in MSTO-211H cells or S phase fractions in 
EHEMS-10 cells (Figure 10c and Table 4). Transduction of mesothelioma cells with the 
siRNA minimally affected the ZOL-decreased cell viability in MSTO-211H cells and slightly 
enhanced the cytotoxicity in EHMES-10 cells (Figure 10d). These data collectively suggested 
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that ZOL-induced cytotoxic and cytostatic effects on human mesothelioma cells were 
independent of the p53 activation. A control siRNA treatment unexpectedly increased 
ZOL-mediated increase of sub-G1 populations in MSTO-211H with minimally influencing 
the expression levels of caspase-9 or -3, which was corresponding to the increase of 
cytotoxicity observed in the WST assay (Figure 10b, 10c and 10d). It could be non-specific 
cytotoxicity of control siRNA in MSTO-211H cells but the mechanism underling is currently 
unknown. 
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Figure 9. ZOL-mediated activation of p53 pathways. (a, b) Cells were treated with (a) CDDP 
(20 μM) or (b) ZOL and then subjected to Western blot analyses. 
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Figure 10. Cytotoxicity of ZOL in p53-mutated and p53-down-regulated cells. (a) Cell cycle 
analyses of p53-mutated mesothelioma cells 48 h after ZOL treatments. (b, c) Cells were 
transfected with 5 nM p53-siRNA or non-specific control siRNA for 24 h and then treated 
with ZOL (50 μM) for 48 h. They were subjected to (b) Western blot analyses or (c) cell cycle 
analyses. (d) Cells were transfected with the siRNA (3 nM) as indicted and treated with ZOL 
for 3 days. The cell viabilities were measured with the WST assay and means of triplicated 
samples with the SE bars are shown. 
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Table 3  Cell cycle distribution of p53-mutated cells after ZOL treatment 
Cell line  Cell cycle distribution (%) ± SE 
 Treatment Time Sub-G1 G0/G1 S G2/M 
JMN-1B      
 (-) 24 h 2.11 ± 0.09a 52.96 ± 0.35 15.10 ± 0.05 28.42 ± 0.37 
  48 h 2.41 ± 0.13a 57.24 ± 0.34 14.86 ± 0.26c 23.64 ± 0.24 
  72 h 2.21 ± 0.03a 62.72 ± 0.04 15.61 ± 0.09c 17.97 ± 0.09 
 ZOL (10 μM) 24 h 2.04 ± 0.11 56.26 ± 0.47 19.70 ± 0.21 20.59 ± 0.23 
  48 h 5.48 ± 0.09a, b 55.95 ± 0.16 22.21 ± 0.28c, d 14.95 ± 0.34 
  72 h 13.98 ± 0.23a, b 50.35 ± 0.23 20.34 ± 0.48c, d 13.50 ± 0.17 
 ZOL (50 μM) 24 h 4.52 ± 0.18a, b 58.39 ± 0.54 16.80 ± 0.32 19.22 ± 0.18 
  48 h 14.84 ± 0.36a, b 56.10 ± 0.17 14.97 ± 0.19d 12.83 ± 0.09 
  72 h 31.01 ± 0.51a, b 46.29 ± 0.28 11.73 ± 0.39c, d 10.09 ± 0.15 
EHMES-1      
 (-) 24 h 8.27 ± 0.32 53.18 ± 0.05 17.77 ± 0.27c 19.12 ± 0.13 
  48 h 7.69 ± 0.44a 64.66 ± 0.29 13.43 ± 0.26c 14.32 ± 0.16 
  72 h 6.77 ± 0.11a 69.40 ± 0.26 11.13 ± 0.16c 11.80 ± 0.05 
 ZOL (10 μM) 24 h 7.20 ± 0.22 54.36 ± 0.29 28.60 ± 0.16c 9.01 ± 0.19 
  48 h 11.84 ± 0.16a, b 36.35 ± 0.16 38.59 ± 0.23c, d 13.43 ± 0.18 
  72 h 30.02 ± 0.33a, b 35.85 ± 0.21 24.12 ± 0.32c, d 9.37 ± 0.38 
 ZOL (50 μM) 24 h 8.92 ± 0.24 57.91 ± 0.61 26.93 ± 0.56c 6.84 ± 0.34 
  48 h 19.85 ± 0.24a, b 37.16 ± 0.32 32.29 ± 0.44c, d 10.01 ± 0.40 
  72 h 38.38 ± 0.19a, b 32.51 ± 0.09 21.56 ± 0.16c, d 6.89 ± 0.11 
Cells were treated with or without ZOL. 
a P < 0.01, not treated vs 10 or 50 μM ZOL treated at respective times in sub-G1 phase. 
b P < 0.01, 10 vs 50 μM ZOL treated at respective times in sub-G1 phase. 
c P < 0.01, not treated vs 10 or 50 μM ZOL treated at respective times in S phase. 
d P < 0.01, 10 vs 50 μM ZOL treated for respective times in S phase. 
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Table 4  Cell cycle distribution of p53-siRNA-transfected cells after ZOL treatment 
Cell line Cell cycle distribution (%) ± SE 
 Treatment Sub-G1 G0/G1 S G2/M 
MSTO-211H     
 (-) 2.35 ± 0.07a 81.69 ± 0.36 6.88 ± 0.29 8.79 ± 0.33 
 Control siRNA 3.13 ± 0.03a 80.66 ± 0.14 7.71 ± 0.04 8.17 ± 0.13 
 p53-siRNA 4.09 ± 0.10a 69.77 ± 0.16 12.10 ± 0.14 13.67 ± 0.11 
 ZOL 34.53 ± 0.23a, b 50.39 ± 0.13 6.12 ± 0.11 8.32 ± 0.29 
 Control-siRNA + ZOL 52.34 ± 0.60a, b 38.23 ± 0.32 3.79 ± 0.08 5.10 ± 0.27 
 p53-siRNA + ZOL 32.96 ± 0.24a 34.31 ± 0.26 17.72 ± 0.34 14.30 ± 0.23 
EHMES-10     
 (-) 5.77 ± 2.32 77.11 ± 1.62 6.66 ± 1.10c 10.39 ± 2.47 
 Control siRNA 3.03 ± 0.39 74.13 ± 1.56 8.92 ± 0.39c 13.42 ± 1.39 
 p53-siRNA 1.36 ± 0.10 74.16 ± 0.11 9.19 ± 0.06c 14.65 ± 0.09 
 ZOL 2.41 ± 0.18 58.21 ± 0.37 27.42 ± 0.34c 12.50 ± 0.31 
 Control-siRNA + ZOL 4.22 ± 0.68 47.51 ± 2.47 35.23 ± 1.43c 13.79 ± 1.67 
 p53-siRNA + ZOL 3.52 ± 0.18 51.54 ± 0.65 33.00 ± 0.31c 12.57 ± 0.20 
Cells were transfected with or without control siRNA or p53-targeting siRNA (p53-siRNA). The 
transfected cells were then treated with or without 50 μM ZOL for 48 h. 
a P < 0.01, not treated vs ZOL treated in cells trasfected with respective siRNA in sub-G1 phase. 
b P < 0.01, not transfected vs control-siRNA-transfected cells in sub-G1 phase. 
c P < 0.01, not treated vs ZOL treated in cells trasfected with respective siRNA in S phase. 
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Involvement of unprenylated small G proteins 
We examined a possible involvement of unprenylated small G proteins in ZOL-induced 
cytotoxicities (Figure 11a). ZOL treatments increased unprenylated forms of Ras and Rap1A, 
which migrated as a higher molecular mass, in MSTO-211H cells. In contrast, the 
ZOL-treated EHMES-10 cells showed Rap1 but not Ras unprenylation. We further examined 
a biological role of the unpreylation in ZOL-induced effects with isoprenoid precursors 
(Figure 11b). Ras and Rap1 are subjected to farnesylation and geranylgeranylation, 
respectively (Figure 1) [11]. FOH and GGOH, membrane-permeable agents, can be 
converted into isoprenoid, FPP and geranylgeranyl pyrophosphate (GGPP), respectively, and 
thus both agents become substrates for prenylation, farnesylation and geranylgeranylation, of 
small G proteins (Figure 13). FOH treatments inhibited ZOL-induced Ras but not Rap1A 
unprenylation or p53 phosphorylation at Ser15. FOH at 10 μM did not influence the 
ZOL-induced cleavage levels of caspase-9 or -3 but the treatment at 30 μM minimally 
enhanced the cleavage in MSTO-211H, which could be due to FOH toxicity (Figure 11b). 
GGOH-treated MSTO-211H cells however showed complete inhibition of ZOL-induced 
Rap1A unprenylation, p53 phosphorylation at Ser15 and the caspase cleavages, and 
interestingly increase of Ras unprenylation. ZOL-induced down-regulation of cyclin A was 
inhibited by GGOH but not by FOH in MSTO-211H cells. Likewise, FOH at 10 μM did not 
influence ZOL-induced the Rap1A prenylation, the p53 phosphorylation or cyclin A 
expression but GGOH at 10 μM inhibited these ZOL-mediated effects in EHMES-10 cells. 
FOH at 30 μM however inhibited the Rap1A unprenylation and the p53 phosphorylation in 
EHMES-10 cells. GGOH at 30 μM could be toxic to EHMES-10 cells and cleaved the 
caspase-9 like FOH at 30 μM in MSTO-211H cells. GGOH also induced Ras unprenylation 
in ZOL-treated EHMES-10 cells as found in MSTO-211H cells.  
We also investigated effects of the isoprenoid precursors with the WST assay and flow 
cytometry (Figure 11c and 11d). Incubation with GGOH but not FOH inhibited 
ZOL-mediated suppression of cell viabilities in MSTO-211H and EHMES-10 cells (Figure 
11c). GGOH also reverted ZOL-mediated increase of sub-G1 phase populations in 
MSTO-211H cells and S phase arrest in EHMES-10 cells (Figure 11d and Table 5), and 
restored the decreased ΔΨm induced by ZOL in MSTO-211H cells (Figure 6e). These data 
collectively suggested that GGOH but not FOH inhibited ZOL-induced effects and that the 
apoptosis and cell cycle changes were attributable to inhibited geranylgeranylation but not 
farnesylation of small G proteins. 
We further confirmed cellular localization of Rho family proteins, RhoA, Cdc42 and Rac1, 
and Rab6 contained in Rab family with Western blot assay using separated fractions of cell 
lysates in MSTO-211H and EHMES-10 cells (Figure 12a). The Rho family proteins and Rab6 
are geranylgeranylated small G proteins, and localized in cytoplasmic and organelle 
membranes, respectively [11]. Farnesylated Ras also was localized in cytoplasmic membrane 
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[12] and ZOL translocated the distribution to the cytoplasm faction in corresponding to the 
unfarnesylation as shown in Figure 11a. Membrane localization of RhoA, Cdc42 and Rab6 
were disturbed with ZOL treatments although redistribution of Rac1 was slightly influenced 
in both cells. We thereby assessed whether a specific inhibitor for geranylgeranyltransferase I 
or II, or for activation of RhoA or Rac1, and a siRNA targeting Cdc42 influenced the cell 
cycle progression as ZOL did (Figure 13). The inhibitors and Cdc42-siRNA however did not 
cause S phase arrest in EHMES-10 cells, whereas high concentration of the inhibitors 
increased sub-G1 phase populations in MSTO-211H cells (data not shown). 
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Figure 11. Geranylgeranylated small G proteins were involved in ZOL-induced effects. (a, b) 
Cells were treated with (a) ZOL or (b) firstly treated with FOH or GGOH for 3 h and then 
with ZOL for 48 h in MSTO-211H cells or for 72 h in EHMES-10 cells. The cell lysates were 
subjected to Western blot analyses. Two bands with high (arrow) and low (dotted arrow) 
molecular weights correspond to unprenylated and prenylated form of Ras and Rap1A. 
#MSTO-211H cells treated with 50 μM ZOL for 24 h as a control. (c) Cells were treated with 
various concentrations of ZOL alone or together with 10 μM GGOH or FOH for 5 days and 
the relative viabilities were measured with the WST assay. Means of triplicated samples with 
SE bars are shown. (d) Cell cycle analyses of cells treated with ZOL (50 μM) or GGOH (10 
μM) alone, or both agents together for 48 h. 
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Table 5  Influence of GGOH on ZOL-induced cell cycle distribution  
Cell line  Cell cycle distribution (%) ± SE 
 Treatment Time Sub-G1 G0/G1 S G2/M 
MSTO-211H      
 (-) 24 h 7.20 ± 0.30a 66.16 ± 1.12 11.84 ± 0.36 15.09 ± 0.94 
  48 h 3.24 ± 0.16a 83.55 ± 0.25 4.01 ± 0.02 9.30 ± 0.41 
  72 h 10.07 ± 0.36a 81.23 ± 0.13 2.77 ± 0.08 5.97 ± 0.28 
 GGOH 24 h 2.57 ± 0.14 62.99 ± 0.07 14.15 ± 0.15 20.66 ± 0.28 
  48 h 3.57 ± 0.15 80.44 ± 0.36 4.59 ± 0.06 11.57 ± 0.20 
  72 h 7.34 ± 0.19 80.91 ± 0.41 3.06 ± 0.13 8.75 ± 0.15 
 ZOL 24 h 30.41 ± 0.97a, b 51.81 ± 0.50 8.56 ± 0.45 9.61 ±0.70 
  48 h 59.08 ± 0.26a, b 34.95 ± 0.27 2.93 ± 0.04 3.20 ± 0.04 
  72 h 82.74 ± 0.50a, b 13.54 ± 0.50 3.36 ± 0.02 0.77 ± 0.03 
 GGOH + ZOL 24 h 15.08 ± 0.20b 55.27 ± 0.12 12.04 ± 0.04 17.91 ± 0.25 
  48 h 12.91 ± 0.12b 68.13 ± 0.44 6.81 ± 0.18 12.36 ± 0.16 
  72 h 9.07 ± 0.11b 69.52 ± 0.32 7.02 ± 0.18 14.71 ± 0.23 
EHMES-10      
 (-) 48 h 0.89 ± 0.10 81.99 ± 0.30 6.60 ± 0.14c 10.72 ± 0.18 
  72 h 0.68 ± 0.06 81.14 ± 0.22 6.07 ± 0.28c 12.20 ± 0.19 
  96 h 0.94 ± 0.09 89.30 ± 0.20 2.79 ± 0.17c 7.08 ± 0.21 
 GGOH 48 h 0.51 ± 0.04 78.91 ± 0.49 7.46 ± 0.12 13.36 ± 0.34 
  72 h 0.67 ± 0.01 83.73 ± 0.09 4.74 ± 0.13 11.00 ± 0.19 
  96 h 1.28 ± 0.12 89.29 ± 0.20 1.95 ± 0.1c 7.59 ± 0.22 
 ZOL 48 h 0.44 ± 0.05 53.73 ± 0.29 34.99 ± 0.17c, d 11.54 ± 0.22 
  72 h 0.82 ± 0.01 44.12 ± 0.15 35.43 ± 0.49c, d 20.04 ± 0.32 
  96 h 2.54 ± 0.24 52.97 ± 0.23 26.27 ± 0.32c, d 18.66 ± 0.19 
 GGOH + ZOL 48 h 0.62 ± 0.05 76.23 ± 0.30 8.05 ± 0.12d 15.29 ± 0.14 
  72 h 0.40 ± 0.04 80.63 ± 0.23 5.02 ± 0.06d 14.08 ± 0.25 
  96 h 1.17 ± 0.11 88.43 ± 0.07 1.58 ± 0.10d 8.89 ± 0.07 
Cells were treated with 50 μM ZOL, 10 μM GGOH or both. 
a P < 0.01, not treated vs ZOL treated at respective times in sub-G1 phase. 
b P < 0.01, ZOL treated vs ZOL and GGOH treated at respective times sub-G1 phase. 
c P < 0.01, not treated vs ZOL treated at respective times S phase. 
d P < 0.01, ZOL treated vs ZOL and GGOH treated at respective times S phase. 
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Figure 12. ZOL-inhibited membrane localization of small G proteins. (a) Cells were treated 
with ZOL (50 μM) and the respective cellular fractions were subjected to Western blot 
analyses. C and M indicate cytoplasm and membrane fractions, respectively. P, positive 
control, is human platelet extract provided by the manufacture. (b) Intensity of the respective 
bands in EHMES-10 cells (a) was shown as relative percentages using Image J program. 
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Figure 13. Prenylation of small G proteins and the related agents. 
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Combinatory cytotoxic effects of ZOL and CDDP 
We investigated combinatory effects of ZOL and CDDP in MSTO-211H and EHMES-10 
cells. We calculated respective IC50 values of each agent to know the optimal test rang and 
then examined cytotoxicity at various doses of both agents with a constant concentration ratio 
according to the CalcuSyn software instruction. Combination of ZOL and CDDP achieved 
cytotoxicity greater than each agent (Figure 14a) and statistical analyses showed that CI 
values at Fa points below 0.8 in MSTO-211H cells were less than 1 and those between 0.15 
and 0.8 Fa points in EHMES-10 cells were under but close to 1 (Figure 14b). These CI values 
demonstrated that both ZOL and CDDP achieved cytotoxicity synergistically in MSTO-211H 
cells and synergistically or additively in EHMES-10 cells. Cell cycle analyses indicated that 
sub-G1 phase populations in ZOL- plus CDDP-treated MSTO-211H cells were greater than 
those in ZOL- or CDDP- treated cells, suggesting that the cytotoxic activities of ZOL and 
CDDP evidenced by the WST assay were due to increased apoptotic cell death in 
MSTO-211H cells (Figure 14c).  
Combinatory effects of ZOL and CDDP in vivo 
We investigated anti-tumor effects of ZOL in combination with CDDP in an orthotopic 
animal model (Figure 15). Nude mice injected with MSTO-211H cells in the pleural cavity 
received ZOL intrapleurally and/or CDDP intraperitoneally. All the tumors were found in the 
pleural cavity without any detectable extrapleural metastatic foci. ZOL or CDDP 
administration inhibited the tumor growth compared with PBS-injected group. We used less 
amounts of ZOL (25 μg) than those (40 μg) in Figure 4, which did not permit ZOL to 
completely inhibit tumor development.  A combinatory administration of ZOL and CDDP 
further decreased tumor weights, demonstrating that the combination produced greater 
therapeutic effects than treatments with a single agent.  
 
Involvement of p53 activation in combinatory effects of ZOL and CDDP 
CDDP treatments produced cytotoxic effects via the p53 pathways in MSTO-211H and 
EHMES-10 cells. The p53 pathways were irrelevant to the ZOL-mediated cytotoxicity 
although ZOL activated p53 and the target molecules. We examined whether the combinatory 
effects between ZOL and CDDP were modulated by p53 expression levels. The p53-siRNA 
treatments suppressed p53 expressions and the phosphorylation as shown in Figure 10b, and 
eliminated the synergistic or additive effects both in MSTO-211H and EHMES-10 cells 
(Figure 16). The CI values of the combination under the siRNA treatments were more than 1, 
which indicated rather antagonistic actions. Activation of p53 did not contribute to the 
ZOL-mediated cytotoxicity but was involved in the combinatory effects of ZOL and CDDP. 
 
Combinatory effects of ZOL and Ad-p53 
We examined whether up-regulated p53 levels by ZOL increased p53-mediated 
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cytotoxicity. Transduction of MSTO-211H cells with Ad-p53 but not Ad-LacZ increased p53 
expressions and induced the phosphorylation at Ser 15 (Figure 17a). Moreover, Ad-p53 but 
not Ad-LacZ decreased the cell viability with a dose-dependent manner (Figure 17b), 
demonstrating that induction of p53 produced cytotoxic effects in MSTO-211H cells. We then 
examined combinatory effects of Ad-p53 and ZOL at a constant ratio between the agents 
(Figure 17c). The combination produced additive or synergistic effects at above 0.15 Fa 
points (Figure 17d) and indicated that up-regulation of p53 by ZOL enhanced 
Ad-p53-mediated cytotoxicity by further activating the p53 pathways. 
 
 
- 38 - 
 
 
Figure 14. Combinatory effects of ZOL and CDDP. (a) Cells were treated with different 
doses of ZOL and CDDP at a constant concentration ratio (ZOL:CDDP=3:2 at each 
concentration in MSTO-211H and 4:3 in EHMES-10 cells) for 3 days and the cell viabilities 
were measured with the WST assay. Means of triplicated samples and the SE bars are shown. 
(b) CI values based on the cell viability as shown in (a) were calculated at different Fa points 
with CalcuSyn software. The SE bars are also indicated. (c) Sub-G1 phase populations of 
PI-stained MSTO-211H cells that were treated with ZOL (15 μM) and/or CDDP (4 μM) for 
24 h were calculated with flow cytometry. Means of triplicated samples and the SE bars are 
shown. * P<0.01. 
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Figure 15. Combinatory effects with ZOL and CDDP in an orthotopic animal model. 
MSTO-211H cells (1X106) were inoculated into the pleural cavity in BALB/c nu/nu mice 
(n=6) and then ZOL (25 μg) and/or CDDP (100 μg) was administrated as shown in Materials 
and Methods. PBS was used as a control. Tumor weights were measured on day 24. The SE 
bars are also shown. * P < 0.05, ** P < 0.01. 
 
 
- 40 - 
 
 
 
Figure 16. Combinatory effects of ZOL and CDDP in p53-down-regulated cells. Cells 
transfected with p53-siRNA (3 nM) were treated with different doses of ZOL and CDDP as 
shown in Figure 14a for 3 days and the CI values based on the cell viability were calculated 
at different Fa points with CalcuSyn software. The SE bars are also indicated. 
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Figure 17. Combinatory effects with ZOL and Ad-p53 (a) Cells were infected with Ad-p53 
or Ad-LacZ (1x103 vp/cell) as a control and were subjected to Western blot analysis. Actin 
was used as a loading control. (b) Cells were infected with Ad-p53 or Ad-LacZ and the cell 
viabilities were measured with the WST assay. Means of triplicated samples and the SE bars 
are shown. (c) Cells were infected with Ad-p53 and/or treated with ZOL at the indicated viral 
amounts and concentrations and cultured for 3 days. The cell viabilities were measured with 
the WST assay. (d) CI values based on the cell viabilities as shown in (c) were calculated at 
different Fa points with CalcuSyn software. The SE bars are also indicated. 
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DISCUSSION 
 
In this study we demonstrated that ZOL alone and the combination with CDDP produced 
anti-tumor effects on mesothelioma in vitro and in vivo. ZOL-induced apoptosis and S phase 
arrest were independent of p53 pathways although ZOL activated p53 pathways. 
Down-regulated p53 levels on the other hand negated the synergism of ZOL and CDDP, 
demonstrating that ZOL produced the combinatory anti-tumor effects by activating p53 
pathways. The present study also suggested that the apoptosis and the cell cycle arrest were 
attributable to ungeranylgeranylation of small G proteins and that the ERK1/2 pathways were 
involved in the apoptosis. 
The majority of human mesothelioma possesses the WT p53 gene but often lacks the 
p14ARF genes, which subsequently suppresses the p53 pathways [3, 28]. ZOL treatments 
up-regulated p53 expression levels and the phosphorylation, and enhanced the expression 
levels of p53 downstream molecules such as Bax and cleaved Mdm2. These data implied that 
the p53 activation could be involved in the apoptosis and the S phase arrest. Transfection of 
p53-siRNA however did not influence the ZOL-induced cell cycle changes, cleavages of 
caspase-3 and -9 in apoptotic cells or cyclin A expression in S phase arrested cells. In 
addition, p53-mutated mesothelioma cells were also susceptible to the ZOL-induced S phase 
arrest and subsequently apoptosis. Time courses of the p53 activation were not completely 
matched to the cell cycle changes. These data collectively indicated that p53 activation did 
not contribute to ZOL-induced apoptosis or S phase arrest. The p53 involvements in 
ZOL-induced cytotoxicity have been controversial but previous studies mentioning the p53 
independent ZOL-mediated activities merely compared the cytotoxicity between the p53-WT 
and the mutated cells [29-31]. The present study however firstly demonstrated the irrelevance 
of p53 by down-regulating p53 with the specific siRNA. Biological significance of 
ZOL-induced p53 activation and the mechanism however remain uncharacterized. GGOH 
supplements moreover decreased ZOL-induced phospholylation of p53, suggesting that the 
p53 activation were caused by inhibited geranylgeranylation of small G proteins. 
ZOL-induced activation of p53 contributed to the cytotoxicity of other agents of which the 
functions were linked with p53 levels. CDDP is one of such agents [32], and combination of 
ZOL and CDDP produced synergistic or additive anti-tumor effects on mesothelioma cells 
and decreased the tumor volumes in an orthotopic animal model. Down-regulation of p53 
with the siRNA however nullified the combinatory effects. These data suggested that 
ZOL-induced p53 up-regulation favored CDDP-mediated cytotoxicity through further 
augmenting the p53 pathways. Benassi et al recently reported similar results with paired cells, 
p53-mutated and the isogeneic p53-WT parent cells from osteosarcoma, that combinatory 
effects of ZOL and CDDP were p53-dependent [31]. The present study moreover analyzed 
the interactions between the two agents in mesothelioma cells and demonstrated synergistic 
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or additive actions in the combination. The interactions became antagonistic under the 
p53-siRNA treatment and it remains currently unknown why it induced the antagonism in the 
combination. ZOL-mediated inhibitory actions on small G proteins were not probably 
influenced by p53 levels or might not enhance the combinatory effects with CDDP because 
down-regulation of p53 did not affect the ZOL-mediated cytotoxicity but lost the 
combination effects. These data consequently suggest that the combinatory effects with 
CDDP were attributable to the ZOL-mediated up-regulated p53 process by itself. 
A combinatory use of ZOL and Ad-p53 also demonstrated that ZOL-mediated 
up-regulation of p53 produced synergistic or additive effects on Ad-p53-induced 
cytotoxicities. Influence of Ad-p53 on unpreylation of small G proteins was less likely 
involved in the combinatory effects for the same reason as discussed above. The present 
study thereby collectively suggests that ZOL has two functions in the cytotoxicity, inhibitory 
actions on small G proteins, which are probably p53-independent, and augmentation of 
endogenous p53 levels in a combinatory use with p53-associated cytotoxicity. We 
demonstrated a possible clinical application of ZOL in combination with CDDP or Ad-p53, 
all of which are currently used in medical treatments and in clinical trials [33]. 
ZOL-induced unprenylation and isoprenoid precursors-induced re-prenylation were 
dependent on small G proteins and cells tested. Rap1A was unprenylated in both ZOL-treated 
MSTO-211H and EHMES-10 cells but Ras unprenylation was observed only in MSTO-211H 
cells. FOH treatments did not influence prenylation of Rap1A except at a high concentration 
in EHMES-10 cells but GGOH completely inhibited Rap1A unprenylation. In contrast, 
GGOH rather increased Ras unprenylation in both cells. Prenlyation of Ras and Rap1A were 
farnesylation and geranylgeranylation processes, respectively [34, 35], and consequently FPP 
(FOH equivalent) and GGPP (GGOH equivalent) induced re-prenylation of Ras and Rap1A, 
respectively [36-41]. The present study however suggest that FOH can be converted into 
GGPP in EHMES-10 cells, which resulted in differential effects of FOH at 30 μM on 
inhibiting Rap1A unprenylation observed in between MSTO-211H and EHMES-10 cells. Our 
data moreover suggested that GGOH could suppress an activity of the FPP syntase or the 
upstream enzyme(s) perhaps HMG-CoA reductase through a possible feedback inhibition and 
subsequently decreased FPP amounts, which resulted in GGOH-induced Ras unprenylation. 
FPP and GGPP pool sizes in respective cells and/or regulations of isoprenoid-synthesizing 
enzymes could differentially influence prenylation processes of small G proteins. 
GGOH-induced Ras unprenylation to our knowledge was firstly demonstrated in the present 
study.  
ZOL-induced effects, apoptosis and S phase arrest, were inhibited by GGOH but not FOH 
treatments. ZOL-mediated growth suppression is thus linked with ungeranylgeranylated but 
not farnesylated small G proteins including Ras. The irrelevance of unfarnesylated Ras in 
ZOL-mediated cytotoxicity was firstly confirmed in the present study. Biological roles of Ras 
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signaling and Ras mutations in mesothelioma have not well studied and mesothelioma might 
be less dependent on Ras activities for their survival. Contribution of geranylgeranylated 
small G proteins to the ZOL-mediated cytotoxicity is one of the issues to be investigated. 
Recently, Roelofs et al. suggested that selective unprenylation of Rab induced apoptosis but 
not S phase arrest [15]. We also demonstrated that C3 transferase and GGTI-298 in addition 
to a Rab granylgeranyltransferae inhibitor, NE10790, increased sub-G1 phase populations in 
MSTO-211H cells but did not induce S phase arrest in EHMES-10 cells (data not shown).  
However, inhibitors, which are irrelevant to functions of small G proteins, also can induce 
cell death in MSTO-211H cells at the high concentrations. In addition, ZOL-treatments 
induced morphological changes which could resemble to those found in C3 
transferase-treated cells (data not shown) but it is uncertain whether RhoA is involved in cell 
growth regulations [42, 43]. We thereby suggest that ZOL-induced S phase arrest and 
apoptosis are resulted from attenuated geranylgeranylation of multiple small G proteins. 
PD98059 decreased ZOL-induced sub-G1 populations but did not influence the S phase 
arrest. The agent also concordantly suppressed capsase-9 and -3 activations in MSTO-211H 
cells but produced little effects on cyclin A expression in EHMES-10 cells. These data 
suggest that the ERK1/2 pathways could modulate cellular responses by ZOL. Previous 
studies showed controversial results whether the third generation of BPs activated ERK1/2 
pathways [13, 30, 36], but the present study demonstrated that the ZOL-mediated ERK1/2 
regulation depended on the cells tested. ZOL induced dephosphorylation of ERK1/2 in 
MSTO-211H cells but enhanced the phosphorylation in EHMES-10 cells. Activation of 
ERK1/2 in ZOL-treated EHMES-10 cells can be inhibitory to the apoptosis in contrast to 
apoptotic MSTO-211H cells, but inhibition of ERK1/2 pathways by PD98059 did not have 
any effects on the cell cycle in EHMES-10 cells. These data collectively implicated that ZOL 
acted on an upstream pathway of the MEK1/2 but ERK1/2 pathways played a cell-type 
dependent role in the ZOL-mediated effects in a complex manner. 
ZOL induced caspases-mediated apoptosis pathways. Caspase-8 and -9, representatives for 
extrinsic and intrinsic pathways, respectively, were cleaved, and capase-3 and PARP were 
also activated. Decreased ΔΨm evidently showed the involvement of the mitochondrial 
intrinsic pathways. Moreover, the caspase-9 cleavage and the suppressed ΔΨm were restored 
by GGOH treatments, demonstrating that activation of the intrinsic pathways contributed to 
ZOL-induced apoptosis. TNF receptor family proteins, located up-stream to the extrinsic 
pathways, were scarcely expressed in mesothelioma (data not shown). ZOL-induced 
caspase-8 cleavage therefore could not be caused by the extrinsic pathways but by caspase-3 
activation as found in anti-cancer agents that induce apoptosis [44, 45]. Caspase-8 in 
mesothelioma was thus alternatively activated by mitochondria-mediated intrinsic pathways. 
In addition, Bcl-2 family proteins including Bax and Mcl-1 modulate ΔΨm [46], which 
suggest that increased Bax and decreased Mcl-1 expression levels in ZOL-treated 
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MSTO-211H cells might be linked with the mitochondria-mediated intrinsic pathways. ZOL 
can increase ATP analogue concentrations and directly activate intrinsic apoptosis pathways 
in a similar mechanism as demonstrated in the first generation of BPs [39]. 
The precise mechanism of S phase arrest with up-regulated cyclin A and B1 remained 
unclear although decreased p21 expression and maintained Rb phosphorylation could 
promote G1/S phase progression and contribute to accumulation of S phase populations [29]. 
Previous reports suggested that ZOL induced DNA damages and subsequently 
ATR/Chk1/Cdc25C or ATM/Chk1/Cdc25A signal transduction pathways were responsible for 
intra-S and G2/M checkpoint mechanisms [29, 47]. We noticed that ZOL treatments 
phosphorylated Chk2 but expression levels of Chk1, Cdc25A, Cdc25B and Cdc25C were not 
correlated the S phase arrest (data not shown). Differential mechanisms regarding whether 
ZOL would induce apoptosis or S phase arrest in mesothelioma cells need further 
investigations. The PD98059 experiments can be a clue since the treatment partially inhibited 
ZOL-induced apoptosis but not S phase arrest. Susceptibility to apoptosis in respective cells, 
which can be determined by a balance between pro-apoptotic and anti-apoptotic activities, 
may play a role in determining whether the cells are subjected to apoptosis or S phase arrest. 
Difference in the endogenous susceptibility in fact can contribute to the cellular difference 
since the IC50 value of CDDP in EHMES-10 was greater than that in MSTO-211H cells (data 
not shown). 
We firstly demonstrated to our knowledge that ZOL suppressed the growth of human 
mesothelioma in in vivo settings. Previous studies also showed that murine mesothelioma, 
developed subcutaneously or in the peritoneal cavity, was treated with ZOL, administrated 
intratumorally or intraperitoneally [37, 48]. In contrast we demonstrated the ZOL-mediated 
anti-tumor effects in an orthotopic experimental model. Previous in vivo studies with other 
tumor types showed that ZOL administrations were effective to suppress the bone metastatic 
lesions [9] since BPs were preferentially accumulated in bone tissues with the rapid clearance 
from serum [10, 49]. This BPs property is disadvantageous as a therapeutic agent to tumors 
developed outside of bone tissues. In fact, we could not observe any growth retardation of 
subcutaneous MSTO-211H tumors with 15 μg ZOL injected systemically (data not shown), 
which corresponded to a mouse equivalent dose of the human dose clinically in use. The 
same amount administered intrapleurally inhibited orthotopic EHMES-10 tumor growths as 
shown in Figure 4a. Mesothelioma, despite of non-osseous origin, is an ideal target for ZOL 
in clinical settings since the intrapleural administration can keep a relative high concentration 
of ZOL compared with the case of intravenous injections. Interestingly, 99mTc-diphosphate, a 
bone scanning agent with a similar structure to BPs, accumulated into pleural effusions [50] 
and was concentrated in mesothelioma [48]. The high affinity of BPs to mesothelium is also 
beneficial when the agent is administered in the pleural cavity. Moreover, calcification can be 
one of the features of mesothelioma [51], which are favorable for a possible use of ZOL as 
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the therapeutic agent. Involvement of g/d T cells activation by ZOL can also contribute to the 
anti-tumor effects [8, 52] although the activation remained uncharacterized in this study. One 
of the concerns in a clinical application of ZOL is possible adverse reactions caused by the 
intrapleural administration. We tested the possibility by injecting 40 mg of ZOL into the 
pleural cavity of C57BL/6 naïve mice. The mice did not show pleura effusion or growth 
retardation of the body weight gain (data not shown). We did not detect any histological 
changes of mesothelia between PBS-injected and ZOL-injected groups (Figure 18).  
The present study moreover showed firstly combinatory anti-tumor effects of ZOL and 
CDDP on mesothelioma in vitro and in vivo. A few studies reported combinatory effects of 
ZOL and CDDP on osseous tumors [31, 53] but theses anti-tumor effects have not been 
evidenced in non-osseous carcinoma. Recent studies showed that ZOL used together with 
other agents, imatinib and doxorubicin, produced greater anti-tumor effects than the agent 
alone in non-osseous tumors, Bcr-Abl-positive leukemina [20] and breast cancer [54], 
respectively. These data indicated that ZOL, even through a systemic administration route, 
produced anti-tumor effects in combination with other cytotoxic agents. The present study in 
vivo suggests that ZOL administered intrapleurally and CDDP injected systemically produce 
a therapeutic benefit to mesothelioma patients. 
In conclusion, we demonstrated that ZOL achieved cytotoxic effects on mesothelioma cells 
by inducing apoptosis through the disruption of ΔΨm and subsequent activation of caspases, 
and by promoting S phase arrest via attenuated p21 expression, both of which were linked 
with inhibition of geranylgeranylation. Combinatory use of ZOL and CDDP or Ad-p53 
produced synergistic effects in the p53-WT mesothelioma cells. ZOL-mediated p53 
up-regulation was not involved in the ZOL-induced cytotoxicity but contributed to the 
combinatory anti-tumor effects of ZOL and CDDP or Ad-p53. Intrapleural administration of 
ZOL eliminated mesothelioma development. Based on the current study we presume that an 
intrapleural injection of ZOL, which is technically feasible but needs a clinical trial for 
testing the safety, in combination with CDDP, the first-line agent for mesothelioma, is in 
particular a potential therapeutics to improve the patient prognosis. 
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Figure 18. Histological pictures of parietal mesothelium of naïve mice injected with PBS or 
ZOL (40 μg) on day 31. Hematoxylin and eosin staining with x20 magnifications. 
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